United Therapeutics Corporation (UTHR)

NASDAQ: UTHR · Real-Time Price · USD

475.45

+3.24 (0.69%)

At close: Sep 25, 2026, 4:00 PM EDT

475.45

0.00 (0.00%)

After-hours: Sep 25, 2026, 5:42 PM EDT

United Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	3,155	3,183	2,877	2,328	1,936	1,686
Revenue Growth	2.49%	10.61%	23.63%	20.20%	14.88%	13.63%
Gross Profit	2,717	2,798	2,568	2,070	1,785	1,563
Operating Income	1,405	1,517	1,452	1,188	989	686.9
Net Income	1,311	1,335	1,195	984.8	727.3	475.8
Earnings Per Share	27.95	27.86	24.64	19.81	15.00	10.06
EPS Growth	9.04%	13.07%	24.38%	32.07%	49.10%	-12.83%

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Tyvaso	1,852	1,878	1,620	1,234	873	607.5
Remodulin	506.8	526.8	538.1	494.8	500.2	513.7
Orenitram	513.6	496.9	434.3	359.4	325.1	306.1
Unituxin	229	226.8	238.7	198.9	182.9	202.3
Adcirca	27.1	30	23.8	28.9	41.3	55.9
Other	25.6	24	22.1	11.8	13.8	0
Revenue (Total)	3,155	3,183	2,877	2,328	1,936	1,686

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	3,803	4,697	4,742	4,904	4,155	3,581
Total Debt	-	37.6	300	700	800	800
Net Cash (Debt)	3,803	4,659	4,442	4,204	3,355	2,781
Net Cash Growth	-23.42%	4.89%	5.67%	25.31%	20.65%	27.28%
Net Cash Per Share	81.10	97.27	91.59	84.59	69.17	58.79

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	1,685	1,561	1,327	978	802.5	598.2
Capital Expenditures	-592.2	-520.5	-246.5	-230.4	-138.8	-120.8
Free Cash Flow	1,093	1,041	1,081	747.6	663.7	477.4
Free Cash Flow Growth	2.05%	-3.69%	44.54%	12.64%	39.02%	-31.45%

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	86.14%	87.92%	89.24%	88.94%	92.17%	92.73%
Operating Margin	44.53%	47.67%	50.44%	51.06%	51.08%	40.75%
Pretax Margin	49.87%	53.85%	53.49%	54.75%	49.09%	35.24%
Profit Margin	41.56%	41.94%	41.53%	42.31%	37.56%	28.23%
FCF Margin	34.65%	32.70%	37.55%	32.12%	34.28%	28.32%

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 25, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	17.01	15.72	13.18	10.49	17.43	20.45
Forward PE	18.33	17.14	12.17	9.93	13.57	13.45
P/FCF Ratio	18.66	20.16	14.58	13.82	19.10	20.38
PS Ratio	6.46	6.59	5.48	4.44	6.55	5.77